Related Experiment Video
Updated: Jun 17, 2026
06:16
Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
Published on: April 19, 2024
A new era in atherothrombosis.
L Badimon1, G Vilahur2, G Mendieta3
1Medical School UVic-UCC, IRIS-CC and Cardiovascular Research Foundation for Health and Innovation, Barcelona, Spain; CiberCV, Institute Carlos III, Barcelona, Spain.
Atherosclerosis
|June 15, 2026
Summary
Atherothrombosis, the cause of cardiovascular diseases, is better understood, leading to improved treatments. Advances in managing atherosclerosis have transformed it into a more controlled condition, improving patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Vascular Biology
- Thrombosis Research
Background:
- Atherothrombosis underlies major atherosclerotic cardiovascular diseases (ASCVDs) like heart attack and stroke.
- Understanding ASCVD pathophysiology, risk, and treatment has significantly advanced.
- Key factors include inflammation, lipid deposition, and immune responses in atherosclerosis progression.
Purpose of the Study:
- To review recent advances in understanding atherothrombosis and its clinical management.
- To highlight the transition of ASCVD from a progressive condition to a more chronic, controlled disease.
- To discuss future directions in therapeutic strategies and diagnostics for atherothrombotic disease.
Main Methods:
- Review of recent scientific literature and clinical evidence.
- Analysis of emerging insights into atherosclerosis mechanisms.
- Evaluation of novel therapeutic agents and diagnostic tools.
Main Results:
- Substantial progress has reshaped the understanding of ASCVD pathophysiology and management.
- Improved therapies have led to better clinical outcomes, modifying the natural history of atherothrombosis.
- ASCVD is increasingly managed as a chronic condition rather than a progressively worsening disease.
Conclusions:
- Continued progress relies on novel therapies targeting atherothrombosis pathways.
- Advances in non-invasive imaging and diagnostics will enable earlier detection and personalized interventions.
- A new era in managing atherothrombotic disease is emerging.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...